Graybug Vision, Inc. (GRAY)
| Market Cap | 734.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 2.82M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $32.01 |
| Previous Close | $35.00 |
| Change ($) | -2.99 |
| Change (%) | -8.54% |
| Day's Open | 34.19 |
| Day's Range | 31.42 - 34.31 |
| Day's Volume | 31,239 |
| 52-Week Range | 12.71 - 35.00 |
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat ...
REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the t...
REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the t...
U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week
Graybug Vision Inc.'s stock started its public life with a rally, as it opened 18.8% above its initial public offering price. The first trade was at $19.00 at 12:15 p.m.
REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to tre...
Graybug Vision Inc. GRAY, +2.59% said early Friday that its upsized initial public offering priced at $16 a share, in the middle of the expected range of $15 to $17 a share.
REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to tre...
Graybug Vision has filed to raise $75 million from the sale of its common stock in a U.S. IPO.
About GRAY
Graybug Vision, a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy;... [Read more...]
| Industry Biotechnology | IPO Date Sep 25, 2020 |
| CEO Dr. Frederic Guerard Pharm.D. | Employees 29 |
| Stock Exchange NASDAQ | Ticker Symbol GRAY |
Analyst Forecasts
According to 5 analysts, the average rating for Graybug Vision stock is "Strong Buy." The 12-month stock price forecast is 35.00, which is an increase of 9.34% from the latest price.